Page:United States Statutes at Large Volume 124.djvu/830

124 STAT. 804 PUBLIC LAW 111–148—MAR. 23, 2010 (3) TITLE XI.—Title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is amended— (A) in section 1128(h)(3)— (i) by inserting ‘‘subtitle 1 of’’ before ‘‘title XX’’; and (ii) by striking ‘‘such title’’ and inserting ‘‘such subtitle’’; and (B) in section 1128A(i)(1), by inserting ‘‘subtitle 1 of’’ before ‘‘title XX’’. Subtitle I—Sense of the Senate Regarding Medical Malpractice SEC. 6801. SENSE OF THE SENATE REGARDING MEDICAL MAL- PRACTICE. It is the sense of the Senate that— (1) health care reform presents an opportunity to address issues related to medical malpractice and medical liability insurance; (2) States should be encouraged to develop and test alter- natives to the existing civil litigation system as a way of improving patient safety, reducing medical errors, encouraging the efficient resolution of disputes, increasing the availability of prompt and fair resolution of disputes, and improving access to liability insurance, while preserving an individual’s right to seek redress in court; and (3) Congress should consider establishing a State dem- onstration program to evaluate alternatives to the existing civil litigation system with respect to the resolution of medical malpractice claims. TITLE VII—IMPROVING ACCESS TO INNOVATIVE MEDICAL THERAPIES Subtitle A—Biologics Price Competition and Innovation SEC. 7001. SHORT TITLE. (a) IN GENERAL.—This subtitle may be cited as the ‘‘Biologics Price Competition and Innovation Act of 2009’’. (b) SENSE OF THE SENATE.—It is the sense of the Senate that a biosimilars pathway balancing innovation and consumer interests should be established. SEC. 7002. APPROVAL PATHWAY FOR BIOSIMILAR BIOLOGICAL PROD - UCTS. (a) LICENSURE OF BIOLOGICAL PRODUCTS AS BIOSIMILAR OR INTERCHANGEABLE.—Section 351 of the Public Health Service Act (42 U.S.C. 262) is amended— (1) in subsection (a)(1)(A), by inserting ‘‘under this sub- section or subsection (k)’’ after ‘‘biologics license’’; and (2) by adding at the end the following: 42 USC 201 note. Biologics Price Competition and Innovation Act of 2009. 42 USC 1320a–7a. 42 USC 1320a–7.